



March 3rd, 2022

Santen to Present Latest Data on Omidenepag Isopropyl
at AGS 2022

Santen Pharmaceutical Co., Ltd. (Head Office in Osaka, hereinafter “Santen”) announced today that a publication of EP2 receptor agonist, omidenepag isopropyl, will be presented at the American Glaucoma Society’s annual meeting (AGS 2022; <https://www.americanglaucomasociety.net/ags-events/annual-meeting>) from March 3rd to 6th, 2022.

Omidenepag isopropyl has been sold in Japan and Asia since 2018 as *EYBELIS Ophthalmic Solution 0.002%*, a treatment for glaucoma and ocular hypertension. In the United States, Santen is preparing for resubmission of the New Drug Application at the end of March 2022.

Presentation topic

Poster #	Title
3149	IOP lowering effect of omidenepag isopropyl (OMDI) versus latanoprost or timolol in the Phase 3 PEONY and Spectrum 4 studies: 3-month subgroup analyses of the effect of age, sex, diagnosis, and prior medication

Contact:

Investor Relations Group

Santen Pharmaceutical Co., Ltd.

E-mail: ir@santen.com